Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company focused on diabetes and obesity care, with its primary political signal being active trading by three members of Congress across 17 transactions in the last 12 months, despite a complete absence of federal contracts, lobbying, and corporate insider buying.
BusinessWhat NVO does
Novo Nordisk is a multinational pharmaceutical company headquartered in Denmark, specializing in the discovery, development, and manufacturing of pharmaceutical products. Its core business areas are diabetes care, obesity care, hemophilia care, and growth hormone therapy, with diabetes and obesity treatments like Ozempic and Wegovy driving significant revenue.
12 months past · 3 months futureNVO activity timeline
Lifetime Government AwardsNVO federal contracts by year
Politicians Trading NVOMembers of Congress with recent NVO positions
Congressional TradesWho in Congress is trading NVO
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills Affecting NVOLive legislation impacting this stock
Political ProfileWhere NVO sits in Washington
[object Object]
STRUCTURAL: High regulatory density (8 impactful healthcare bills) but zero lobbying spend (`get_political_influence.lobbying.total_income`: $0) and no federal contracts (`get_government_precedent.federal_contracts_summary`: null). EVIDENTIARY: Active congressional trading (17 transactions by 3 members) and a single executive branch holding (`get_executive_branch_exposure.by_ticker[0].positions`: 1), but zero corporate insider buys in 180 days (`get_corporate_insider_signal.total_buys`: 0). Net: Evidentiary interest from government officials is contradicted by a complete lack of structural political engagement, resulting in a neutral net signal.
Regulatory ExposureThreats & opportunities
Regulatory threats
-
Heightened legislative scrutiny and potential pricing regulations for GLP-1 drugs.U.S. Congress, HHS, CMS"`Recent bill_impacts` shows 8 healthcare bills with material estimated revenue impacts, indicating high regulatory density."
Regulatory opportunities
-
Expanded Medicare/Medicaid coverage for obesity pharmacotherapy.CMS"No direct evidence in provided RPC fields; opportunity inferred from sector and product focus, but not evidenced."
Capitol Hill AlliesChampions & critics
Congressional champions
Congressional critics
- No specific congressional critics identified.
Live signals + predictions for NVO — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades NVO
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord